A prospective single‐institution study of intraoperative radiotherapy (IORT) for early‐stage breast cancer

2020 ◽  
Author(s):  
My‐Lien Nguyen ◽  
Patricia Pius ◽  
William Dooley ◽  
Ronald Squires ◽  
Ozer Algan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Intraoperative Radiotherapy ◽  
Early Stage Breast Cancer ◽  
Single Institution

scholarly journals Review of current perspectives on low-energy X-ray intraoperative radiotherapy in early stage breast cancer

2019 ◽  
Vol 3 ◽  
pp. 12-12
Author(s):  
Yang-Hong Dai ◽  
Yu-Jen Chen ◽  
Chun-Shu Lin ◽  
Kuen-Tze Lin ◽  
Wen-Yen Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Intraoperative Radiotherapy ◽  
Low Energy ◽  
Early Stage Breast Cancer ◽  
X Ray

scholarly journals Efficacy, late complications, and cosmetic outcomes of targeted intraoperative radiotherapy in breast-conserving surgery for early-stage breast cancer: a single-centre study in China

2019 ◽  
Vol 49 (12) ◽  
pp. 1120-1125 ◽  
Author(s):  
Yin Mi ◽  
Pengwei Lv ◽  
Fang Wang ◽  
Lin Li ◽  
Mingzhi Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Intraoperative Radiotherapy ◽  
Late Complications ◽  
Outcome Evaluation ◽  
Early Stage Breast Cancer ◽  
Chinese Patients ◽  
Breast Cancer Patients ◽  
Cosmetic Outcomes

Abstract Objective The purpose of this study was to evaluate the efficacy, late complications, and cosmetic outcomes of targeted intraoperative radiotherapy for the treatment of Chinese patients with early-stage breast cancer. Methods Between September 2014 and May 2017, breast cancer patients undergoing targeted intraoperative radiotherapy at our facility were retrospectively recruited for this study. Intraoperative radiotherapy was performed with a 50-kV X-ray source in an Intrabeam system (Carl Zeiss Meditec, Oberkochen, Germany). The one-time prescribed irradiation dose to the tumour bed was 20 Gy. Recurrence, death, late complications, and cosmetic outcomes were recorded. Late radiotoxicity was assessed based on the grading criteria of the Radiation Therapy Oncology Group. Results A total of 77 patients who were treated with targeted intraoperative radiotherapy only were recruited. The cohort had a mean age of 58 years; patients with T1, N0, and invasive ductal carcinoma accounted for 75.3, 89.6, and 84.4%, respectively; the median follow-up duration was 40 months; there were 2 patients of recurrence and 2 patients of death. There were no patients of cardiac toxicity or skin or lung radiotoxicity of grade 2 or above. The main complications were breast oedema (18.2%), seroma (15.6%), chromatosis (9.1%), induration (7.8%), pain (5.2%), skin depression (2.6%), mild dry cough (2.6%), delayed wound healing (1.3%), and wound infection (1.3%). Seventy-three patients participated in the cosmetic outcome evaluation, which yielded an excellent or good rate of 95.9%. Conclusions Due to its low recurrence rates, lack of high-grade late radiotoxicity, and excellent cosmetic outcomes, targeted intraoperative radiotherapy may be a suitable treatment for select early-stage breast cancer patients in China.

scholarly journals Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Linwei Wang ◽  
Min Sun ◽  
Shuailong Yang ◽  
Yuanyuan Chen ◽  
Tian Li
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Therapeutic Option ◽  
Meta Analysis ◽  
Intraoperative Radiotherapy ◽  
Recurrence Risk ◽  
Early Stage Breast Cancer ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

ObjectiveIntraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-analysis to compare the efficacy and safety of IORT to those of WBRT as therapeutic options for early-stage breast cancer patients receiving breast-conserving surgery (INPLASY2020120008).MethodsPubMed, Embase, and Cochrane Library databases were searched from inception to October 2021. Computerized and manual searches were adopted to identify eligible randomized control trials from online databases. Risk ratio (RR) and 95% confidence intervals (CI) were calculated by random-effect models to assess the relative risk. Potential publication bias was quantified by Begg’s and Egger’s tests.ResultsBased on our inclusion criteria, 10 randomized control trials involving 5,698 patients were included in this meta-analysis. This meta-analysis showed that the IORT group was associated with a higher local recurrence risk (RR = 2.111, 95% CI, 1.130–3.943, p = 0.0191), especially in the long-term follow-up subgroup or published after 2020 subgroup or Caucasian subgroup (RR = 2.404, 95% CI, 1.183–4.885, p = 0.0154). Subgroup analysis showed that the IORT group had a higher recurrence risk than the WBRT group in the polycentric randomized controlled trial subgroup (RR = 1.213, 95% CI, 1.030–1.428, p = 0.0204). Pooled analysis showed that there was no statistically significant difference in overall survival, recurrence-free survival, distant metastasis-free survival, and cancer-specific survival between IORT and WBRT groups. Additionally, the risk of skin toxicity was reduced, but the incidences of fat toxicity, edema, and scar calcification were significantly increased in the patients who underwent IORT in comparison to those who underwent WBRT.ConclusionThis meta-analysis revealed that IORT was not a better alternative to WBRT. More large-scale and well-designed clinical trials with longer follow-up periods are encouraged to further investigate the value of IORT.Systematic Review Registrationhttps://inplasy.com/inplasy-2020-12-0008/.

Sign in / Sign up

Export Citation Format

Share Document